CBU
KYMR icon

CIBC Bancorp USA’s Kymera Therapeutics KYMR Stock Holding History

CIBC Bancorp USA’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$398K Buy
3,471
+579
+20% +$49.7K ﹤0.01% 1391
2026
Q1 		$241K Buy
+2,892
New +$229K ﹤0.01% 1522
2025
Q3 		$304K Buy
+5,375
New +$242K ﹤0.01% 1080

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CIBC Bancorp USA's KYMR Position: Q2 2026 in Review

CIBC Bancorp USA increased its Kymera Therapeutics (KYMR) stake by 20% in Q2 2026, buying an estimated $49.7K and bringing the position to 3,471 shares worth $398K. The position accounts for ﹤0.01% of the portfolio, ranked #1391.

CIBC Bancorp USA first reported a position in KYMR in Q3 2025 and has held it in 3 quarters since. 255 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • CIBC Bancorp USA held 3,471 shares of Kymera Therapeutics worth $398K as of Q2 2026.
  • CIBC Bancorp USA bought 579 Kymera Therapeutics shares in Q2 2026, an estimated $49.7K.
  • Kymera Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1391 holding.
  • CIBC Bancorp USA first reported a position in Kymera Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 255 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.